Payment overview · 2025
General Payments
$941.81
48 reported records · 19 companies
Healthcare provider profile · identity verified
Anna Dumas, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DECATUR, AL · NPI 1831408350
Verified facts
What the public records show
CMS Open Payments records show Anna Dumas, CRNP received $941.81 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $187.34 | 19.9% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $161.97 | 17.2% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $94.46 | 10.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.01 | 6.4% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.84 | 6.2% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $48.35 | 5.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.98 | 4.8% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $38.51 | 4.1% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.44 | 3.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.99 | 3.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.97 | 2.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.33 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.89 | 2.3% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.22 | 2.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.00 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.60 | 2.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.91 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.73 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.27 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $941.81 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.82 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $126.82 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $97.82 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $94.46 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $89.96 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.57 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.52 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $60.01 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $58.84 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $48.35 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.98 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $38.51 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.99 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.99 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 197 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
90 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
137 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
197 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 572 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 488 | 143 |
| Omeprazole | Omeprazole | 449 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 400 | 138 |
| Tizanidine Hcl | Tizanidine Hcl | 376 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 318 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 102 |
| Lisinopril | Lisinopril | 270 | 98 |
| Clonazepam | Clonazepam | 235 | 35 |
| Celecoxib | Celecoxib | 232 | 82 |
| Montelukast Sodium | Montelukast Sodium | 201 | 80 |
| Ozempic | Semaglutide | 197 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 50 |
| Pregabalin | Pregabalin | 192 | 35 |
| Azithromycin | Azithromycin | 187 | 126 |
| Furosemide | Furosemide | 171 | 55 |
| Tramadol Hcl | Tramadol Hcl | 171 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 66 |
| Meloxicam | Meloxicam | 157 | 60 |
| Trazodone Hcl | Trazodone Hcl | 151 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 54 |
| Metformin Hcl | Metformin Hcl | 144 | 51 |
| Methylprednisolone | Methylprednisolone | 144 | 110 |
| Farxiga | Dapagliflozin Propanediol | 139 | 34 |
| Losartan Potassium | Losartan Potassium | 139 | 44 |
| Metformin Hcl Er | Metformin Hcl | 139 | 49 |
| Mounjaro | Tirzepatide | 137 | 28 |
| Promethazine Hcl | Promethazine Hcl | 135 | 24 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 128 | 18 |
| Potassium Chloride | Potassium Chloride | 127 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 123 | 46 |
| Glimepiride | Glimepiride | 120 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 41 |
| Famotidine | Famotidine | 112 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 112 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 31 |
| Cefdinir | Cefdinir | 101 | 71 |
| Jardiance | Empagliflozin | 100 | 27 |
| Carvedilol | Carvedilol | 97 | 40 |
| Levofloxacin | Levofloxacin | 96 | 70 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 25 |
| Linzess | Linaclotide | 90 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 81 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 13 |
| Alprazolam | Alprazolam | 79 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 25 |
| Fluconazole | Fluconazole | 70 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 23 |
| Ondansetron Odt | Ondansetron | 67 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 25 |
| Vraylar | Cariprazine Hcl | 66 | suppressed |
| Diazepam | Diazepam | 65 | 12 |
| Ibuprofen | Ibuprofen | 65 | 17 |
| Methocarbamol | Methocarbamol | 65 | 18 |
| Mupirocin | Mupirocin | 65 | 51 |
| Simvastatin | Simvastatin | 64 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 41 |
| Allopurinol | Allopurinol | 59 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 20 |
| Lorazepam | Lorazepam | 55 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Buspirone Hcl | Buspirone Hcl | 53 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 12 |
| Sertraline Hcl | Sertraline Hcl | 50 | 15 |
| Eliquis | Apixaban | 46 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 13 |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Topiramate | Topiramate | 44 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 38 |
| Mirtazapine | Mirtazapine | 43 | 18 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Aripiprazole | Aripiprazole | 39 | 12 |
| Baclofen | Baclofen | 39 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | 11 |
| Estradiol | Estradiol | 37 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 21 |
| Nystatin | Nystatin | 34 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 19 |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Metronidazole | Metronidazole | 33 | 29 |
| Atenolol | Atenolol | 32 | suppressed |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Naproxen | Naproxen | 32 | 12 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Risperidone | Risperidone | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 15 |
| Ketoconazole | Ketoconazole | 29 | 21 |
| Valsartan | Valsartan | 29 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | 11 |
| Lacosamide | Lacosamide | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Permethrin | Permethrin | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Prednisone | Prednisone | 23 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Trulance | Plecanatide | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 18 |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Lactulose | Lactulose | 20 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 12 |
| Glipizide | Glipizide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 18 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Rybelsus | Semaglutide | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $941.81 · 48 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, FANAPT, FARXIGA, GEMTESA, GVOKE HYPOPEN, INSPIRE, JARDIANCE, JOURNAVX, Korlym, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error